文献速递造血干细胞移植与细胞治疗淋巴瘤

单倍体造血干细胞移植中的细胞因子释放综合征可能影响T细胞恢复与复发

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse.
PubMed 文献 · Blood Adv · 2023-01-01

这项单中心回顾性研究纳入2011至2020年间169例接受单倍体造血干细胞移植的患者,其中98例(58%)发生移植后细胞因子释放综合征(CRS)。CRS与疾病复发率降低相关(P = .024),但慢性移植物抗宿主病风险增加(P = .01);CRS患者移植后1个月CD4+调节性T细胞(P < .0005)、CD4+常规T细胞(P < .005)和CD8+ T细胞(P < .005)较无CRS者升高,但后期时间点无差异。作者指出需在多中心队列中验证这些观察结果。

要点

  • 单倍体移植后58%(98/169)患者发生CRS,CRS与复发率降低相关(P = .024)。
  • CRS与慢性GVHD风险增加相关(P = .01)。
  • CRS患者移植后1个月T细胞及亚群升高,但后期时间点无差异。

核心结论

  • 单倍体移植后CRS与疾病复发率降低相关,并对移植后T细胞及其亚群的免疫重建有一过性影响。
  • 作者指出需在多中心队列中验证这些观察结果。

研究设计与样本

  • 单中心回顾性研究,纳入2011至2020年间接受单倍体造血干细胞移植的169例患者。
  • CRS根据移植后前5天内出现发热且无感染或输注反应证据进行诊断,并按既定标准分级。

主要发现

  • 169例患者中98例(58%)在移植后发生CRS。
  • 移植后CRS与疾病复发率降低相关(P = .024),且该关联不受移植物来源或疾病诊断混杂。
  • 移植后CRS与慢性移植物抗宿主病风险增加相关(P = .01)。
  • CD34或总有核细胞剂量与CRS的关联不独立于移植物类型。
  • 发生CRS的患者移植后1个月CD4+调节性T细胞(P < .0005)、CD4+常规T细胞(P < .005)和CD8+ T细胞(P < .005)较未发生CRS者升高,但后期时间点无差异。

关键数值与推荐

  • CRS诊断标准为移植后前5天内出现发热且无感染或输注反应证据,并按既定标准分级。
  • 接受骨髓移植的CRS患者移植后1个月CD4+调节性T细胞升高最为显著(P < .005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为单中心回顾性研究。
  • 作者指出需在多中心队列中验证这些观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytokine release syndrome (CRS) following haploidentical hematopoietic cell transplantation (HCT) resembles CRS after chimeric antigen receptor-T therapy. We conducted this single-center retrospective study to evaluate the association of posthaploidentical HCT CRS with clinical outcomes and immune reconstitution. One hundred sixty-nine patients who underwent haploidentical HCT between 2011 and 2020 were identified. Of these, 98 patients (58%) developed CRS after HCT. CRS was diagnosed based on the presence of fever within the first 5 days after HCT without evidence of infection or infusion reaction and was graded according to established criteria. The development of posthaploidentical HCT CRS was associated with a lower incidence of disease relapse (P = .024) but with an increased risk of chronic graft-versus-host disease GVHD (P = .01). The association of CRS with a lower incidence of relapse was not confounded by graft source or disease diagnosis. Neither CD34 nor total nucleated cell dose was associated with CRS independently of graft type. In patients developing CRS, CD4+ Treg (P < .0005), CD4+ Tcon (P < .005), and CD8+ T cells (P < .005) increased 1 month after HCT compared with those who did not develop CRS, but not at later time points. The increase in CD4+ regulatory T cells 1 month after HCT was most notable among patients with CRS who received a bone marrow graft (P < .005). The development of posthaploidentical HCT CRS is associated with a reduced incidence of disease relapse and a transient effect on post-HCT immune reconstitution of T cells and their subsets. Therefore, the validation of these observations in a multicenter cohort is required.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shapiro RM, Kim HT, Ansuinelli M, et al. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023. PMID: 37216223. doi:10.1182/bloodadvances.2023009657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。